ARRHYTHMIA RESEARCH TECHNOLOGY, INC. and OSMETECH Announce a 3-Year Supply Agreement.

FITCHBURG, Mass. -- Arrhythmia Research Technology, Inc. (AMEX: HRT) announced that its wholly owned subsidiary Micron Products Inc. ("Micron"), has entered into a three-year supply agreement with the Molecular Diagnostics division of Osmetech plc (LSE: OMH). Micron, through its New England Molders division ("NEM"), will provide manufacturing services for consumables components used in Osmetech's OPTI TUBE[TM] and OPTI GENE[TM] product lines.

The OPTI TUBE[TM] product line consists of patented plastic tubes with ergonomic sealing caps and carousel which have been designed as a replacement for the glass capillaries which are used in the Roche LightCycler[R]. OPTI TUBE[TM] is a robust alternative solution with excellent optical and thermal properties that eliminates the dangers of glass breakage and minimizes the risk of laboratory personnel exposure to potentially dangerous samples and glass shards. The OPTI TUBE[TM], developed from combined efforts by Osmetech and NEM engineers, have resulted in a cost effective alternative to glass.

Osmetech's OPTI GENE[TM] instrument is specifically designed to meet the requirements of the molecular diagnostic market in the small to medium sized hospital. This product is designed to enable simple and more complex molecular diagnostic tests to be performed accurately in a cost effective and easy to use format and meet the increasing demand for genetic tests to improve disease management.

James E. Rouse, President and CEO of Arrhythmia Research Technology, Inc., commented, "We are very pleased to have been chosen by Osmetech as the manufacturer of its disposables for the OPTI TUBE[TM] and OPTI GENE[TM] product lines This agreement has significant long term benefits to both Micron and Osmetech. The opportunity to support a company such as Osmetech as it grows into a leading player in the field of molecular diagnostics is a great opportunity for our NEM division and the company as a whole, and will be the first of many products to be manufactured in our new class 100,000 clean room. The close working relationship between the two companies will continue as we strive to expand the scope of our supply agreement to additional product groups and value added services. The agreement demonstrates the establishment of a mutually beneficial customer /supplier relationship. Micron's expansion into test products for the molecular diagnostics industry complements the current line of high quality medical products we manufacture."

James White, CEO of Osmetech said, "We are excited to be working with Micron Products. Micron's customer focus and commitment to quality made for an easy decision in the selection of Micron as our partner for the manufacture of our molecular diagnostic disposables. The OPTI TUBE[TM] product has recently been launched and has demonstrated excellent performance in comparative studies between the Roche glass capillaries and our plastic tubes."

About Arrhythmia Research Technology, Inc.

ART, through Micron, manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron's NEM division manufactures custom injection molded products for medical, electronic, industrial and consumer applications. Micron's MIT division provides end- to- end product life cycle management through a comprehensive portfolio of value-added services such as design, engineering, prototyping, manufacturing, machining, assembly and packaging. Micron's Leominster Tool division provides high end mold design and manufacturing for the injection molding industry. The Company's products also include proprietary signal-averaging electrocardiography (SAECG) software used in the detection of potentially lethal hearth arrhythmias.

For more information please check our websites:

http://www.arthrt.com

http://www.micronproducts.com

http://www.leominstertool.com

http://www.newenglandmolders.com

http://www.micronintegrated.com

About Osmetech plc

Osmetech plc is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international diagnostics business with operations in Atlanta, Boston and Pasadena in the US, serving the high growth, near patient testing market targeting small to medium sized hospitals. Osmetech has launched eSensor[R], an FDA cleared electrochemistry-based array system, for Cystic fibrosis carrier detection and will launch a number of pharmacogenomic assays utilizing our proprietary technology in the near future. Roche LightCycler[R], OPTI TUBE[TM] OPTI GENE[TM] and eSensor[R] are trademarks of Osmetech plc.

About Osmetech's Molecular Diagnostics Division

The molecular diagnostics market continues to grow with an increasing demand for both new and existing genetic tests to improve disease management. Osmetech's eSensor[R] and OPTI GENE[TM] instruments are specifically designed to meet the requirements of this rapidly growing and decentralizing market. The combination of these products should enable simple and more complex molecular diagnostic tests to be performed accurately in a cost effective and easy to use format. Unlike many competing products, both Osmetech products combine an instrument platform and proprietary assay-specific consumables.

For more information:

Osmetech Molecular Diagnostics

Geoffrey A. McKinley, Ph.D.

Vice President Business Development

Phone: [phone] ext. 7108

Fax: [phone]

Email: [e-mail]

http://www.osmetech.com

Note Regarding Forward Looking Statements

Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks, changing economic conditions in developing countries, and an inability to arrange additional debt or equity financing. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005.